Hemab Therapeutics adds Keli Walbert to board and audit committee
The company disclosed in an 8-K that Walbert joined the board effective September 24, 2026, with a standard option grant and cash compensation package.
SEC filing
Latest
2 stories
Thursday, September 24
Tuesday, August 11
Hemab reports Q2 2026 results as FDA clears sutacimig path to Phase 3 in Glanzmann thrombasthenia
The company also unveiled a new bleeding-disorder candidate, HMB-003, and posted early HMB-002 data in Von Willebrand disease.
SEC filing